Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: Coban 45
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
22373-78-0 76196-81-1
4316-73-8 64665-57-2
7646-75-5 31121-93-4
1981-58-4 68244-58-6
78126-10-0 87713-30-2

22373-78-0

22373-78-0 structure
22373-78-0 structure
  • Name: Monensin sodium salt
  • Chemical Name: Monensin sodium salt
  • CAS Number: 22373-78-0
  • Molecular Formula: C36H61NaO11
  • Molecular Weight: 692.85
  • Catalog: API Antiparasitic drug Antiprotozoal
  • Create Date: 2018-05-04 08:00:00
  • Modify Date: 2024-01-02 19:49:50
  • Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis.
Name Monensin sodium salt
Synonyms Monensin Sodium (200 mg)
Monensin sodium
Coban
MONENSINSODIUM,USP
RUMENSIN
EINECS 244-941-7
monensin A sodium
Monensin Sodium Salt
Sodium Monensin
Monensin A sodium salt
monensin,monosodiumsalt
Coban45
Monensim A sodium salt
Description Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis.
Related Catalog
Target

bacterial[1]
In Vitro Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Untreated cells display 2.5% apoptosis; 48 hours treatment with 1 μM Monensin sodium salt shows 4.5% apoptosis whereas 5 μM Monensin sodium salt for 48 hours induces a greater apoptotic response (16.4%). Pretreatment with either 1 or 5 μM Monensin sodium salt for 24 hours followed by 10 μM erlotinib treatment for another 24 hours results in a marked increases in apoptotic events (14.6% and 38.7%, respectively) when compare with either Monensin sodium salt or erlotinib treatments alone. Combination of 5 μM Monensin sodium salt with 10 μM erlotinib shows the highest percentage of apoptosis (38.7%)[1].
In Vivo Although the numbers of tumors do not change substantially, a significant (P=0.0144) reduction in the average size of lesions is observed in Monensin sodium salt-treated Apc+/Min mice when compare with control animals (mean 0.199 mm2 vs. 0.299 mm2). The total tumor area estimated in one animal is decreased in individuals receiving Monensin sodium salt (mean 10.16 mm2 vs. 16.46 mm2; P=0.0125). Monensin sodium salt treatment increases the numbers of apoptotic cells and cells expressing the p21 cell-cycle inhibitor at the surface area of the neoplastic outgrowths. No changes in the cell proliferation, differentiation, and tissue architecture in the healthy parts of mucosa are noted after exposure to Monensin sodium salt[2].
Cell Assay One million SCC25 cells are seeded in 10-cm plates and incubated overnight to allow for attachment and recovery. The following day, cells are pretreated with 0, 1, or 5 μM Monensin sodium salt for 24 hours then treated with 10 μM erlotinib alone or in combination with Monensin sodium salt for a further 24 hours. Adherent and cells in suspension are collected by centrifugation and fixed in 3 mL of cold 80% ethanol overnight at -20°C. Before analysis, cell pellets are washed with PBS resuspended in staining buffer containing 25 μg/mL propidium iodide and 40 μg/mL RNase A and incubated for a minimum of 1 hour in the dark at room temperature[1].
Animal Admin Multiple intestinal neoplasia (Min) mice are used in this study. Four-week-old pups are weaned, genotyped, and randomized. The animals are divided into two groups and treated with Monensin sodium salt (10 mg/kg) or vehicle (DMSO). Daily oral applications continue for 6 weeks. In addition, six pairs of Apc+/Min mice age 7, 10, 13, 16, 19, and 22 weeks are treated with Monensin sodium salt or vehicle for 5 weeks. The mice are sacrificed and the intestines are dissected, washed in PBS, and fixed in 4% formaldehyde (v/v) in PBS for 3 days. Fixed intestines are embedded in paraffin, sectioned and stained. The number and size of the neoplastic lesions are quantified using Ellipse software[2].
References

[1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.

[2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.
Boiling Point 766.3ºC at 760 mmHg
Melting Point 267-269ºC
Molecular Formula C36H61NaO11
Molecular Weight 692.85
Flash Point 229.2ºC
PSA 165.43000
LogP 2.87390
Vapour Pressure 4.13E-27mmHg at 25°C
Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H300
Precautionary Statements P264-P301 + P310
Personal Protective Equipment Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes T:Toxic;
Risk Phrases R25
Safety Phrases S45
RIDADR UN 3462 6.1/PG 2
WGK Germany 3
RTECS JH2830000
Packaging Group II
Hazard Class 6.1(a)
Precursor  1

DownStream  3



Chemsrc provides CAS#:22373-78-0 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 22373-78-0 | Chemsrc address: https://www.chemsrc.com/en/baike/751633.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved